At Camber, 2025 is a year of strong momentum. With a strong wave of new generic product launches already in motion, we’re demonstrating our commitment to innovation, agility, and market leadership. And we’re far from done. A steady pipeline of ANDA approvals, fresh filings, and strategic launches—including several Day-1 opportunities—is set to propel us even further. As we expand access to cutting-edge therapies, we also continue to strengthen our legacy portfolio, ensuring a consistent, trusted supply of essential medications nationwide.
Allopurinol Tablets
Camber launched Allopurinol Tablets (generic for Zyloprim®) in the spring of 2024. Allopurinol Tablets, USP are indicated for 1) the management of patients with signs and symptoms of primary or secondary gout, 2) the management of patients with conditions requiring therapies which cause elevations of serum and urinary uric acid levels, 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds specific thresholds. Learn More
Ivabradine Tablets
Ivabradine Tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. Camber added this medication to our portfolio in July 2024, reinforcing our commitment to advancing cardiovascular health. Learn More
Olmesartan Medoxomil Tablets
Earlier this year, Camber added Olmesartan Medoxomil Tablets (generic for Benicar®) to our portfolio. Olmesartan Medoxomil Tablets are an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adult and pediatric patients six years of age and older, either alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Learn More
